168 related articles for article (PubMed ID: 8695969)
21. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
[TBL] [Abstract][Full Text] [Related]
22. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
23. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
[TBL] [Abstract][Full Text] [Related]
24. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.
Ongphiphadhanakul B; Piaseu N; Tung SS; Chailurkit L; Rajatanavin R
Maturitas; 2000 Feb; 34(2):179-84. PubMed ID: 10714913
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Kovács AB
Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study.
Kaari C; Haidar MA; Júnior JM; Nunes MG; Quadros LG; Kemp C; Stavale JN; Baracat EC
Maturitas; 2006 Jan; 53(1):49-58. PubMed ID: 16257151
[TBL] [Abstract][Full Text] [Related]
27. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
28. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial.
Recker RR; Davies KM; Dowd RM; Heaney RP
Ann Intern Med; 1999 Jun; 130(11):897-904. PubMed ID: 10375338
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women.
Notelovitz M; John VA; Good WR
Menopause; 2002; 9(5):343-53. PubMed ID: 12218723
[TBL] [Abstract][Full Text] [Related]
30. Lack of any estrogenic effect of ipriflavone in postmenopausal women.
Melis GB; Paoletti AM; Cagnacci A; Bufalino L; Spinetti A; Gambacciani M; Fioretti P
J Endocrinol Invest; 1992 Nov; 15(10):755-61. PubMed ID: 1491124
[TBL] [Abstract][Full Text] [Related]
31. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
Meschia M; Brincat M; Barbacini P; Maini MC; Marri R; Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 1992 Oct; 47(1):53-7. PubMed ID: 1330761
[TBL] [Abstract][Full Text] [Related]
32. [Ipriflavone].
Kitatani K; Morii H
Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
[TBL] [Abstract][Full Text] [Related]
33. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
[TBL] [Abstract][Full Text] [Related]
34. Is 1 mg of estradiol valerate or 0.625 mg of conjugated estrogens sufficient for all women to prevent menopausal bone loss?
Duursma SA; de Raadt M; Raymakers JA; Haspels AA
Gynecol Endocrinol; 1992 Sep; 6(3):205-9. PubMed ID: 1332428
[TBL] [Abstract][Full Text] [Related]
35. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
[TBL] [Abstract][Full Text] [Related]
36. Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen.
Domrongkitchaiporn S; Ongphiphadhanakul B; Stitchantrakul W; Chansirikarn S; Puavilai G; Rajatanavin R
Maturitas; 2002 Feb; 41(2):149-56. PubMed ID: 11836046
[TBL] [Abstract][Full Text] [Related]
37. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
38. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
Jayo MJ; Register TC; Carlson CS
Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
[TBL] [Abstract][Full Text] [Related]
39. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
de Aloysio D; Gambacciani M; Altieri P; Ciaponi M; Ventura V; Mura M; Genazzani AR; Bottiglioni F
Gynecol Endocrinol; 1997 Aug; 11(4):289-93. PubMed ID: 9272427
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
